BiolineRx

Company Overview

Snapshot

Founded in April 2003, BiolineRx operates with 51–200 employees and has raised a total of $208.64 million across 18 funding rounds from 10 investors. In September 2023, the company received FDA approval for APHEXDA™ (motixafortide) in combination with filgrastim (G-CSF) for stem cell mobilization in multiple myeloma patients.

Business overview

BiolineRx is a clinical-stage biopharmaceutical company specializing in oncology. The company's pipeline includes BL-8040, a platform for various cancer and hematological indications, and AGI-134, a synthetic immunotherapy for solid tumors. BioLineRx identifies, validates, and in-licenses therapeutic candidates that offer advantages over existing treatments or address unmet medical needs. The company also collaborates with Novartis on drug candidates and with MSD (Merck) for a Phase 2a study in pancreatic cancer using BL-8040 and Keytruda. BioLineRx operates within the Health Tech & Life Sciences sector, focusing on drug discovery and development, particularly in pharmaceuticals and biologicals.

Strategic signal

In September 2025, BioLineRx Ltd. and Hemispherian AS established a joint venture to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other cancers. This collaboration signals BioLineRx's strategic expansion into novel immunotherapy approaches and its commitment to addressing challenging cancer types, potentially opening new avenues for treatment and market opportunities.

Company Intelligence Q&A

What was a significant regulatory milestone for BioLineRx in 2023?

In September 2023, BioLineRx announced FDA approval of APHEXDA™ (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.

What strategic partnership did BioLineRx form in September 2025?

In September 2025, BioLineRx Ltd. and Hemispherian AS established a joint venture to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other cancers.

What was the focus of BioLineRx's digital resource launched in September 2024?

In September 2024, BioLineRx launched 'Mobilization Matters,' a digital resource designed for people with multiple myeloma who are preparing for stem cell collection.

What patent allowance did BioLineRx announce in October 2024?

In October 2024, BioLineRx announced the USPTO allowance of a new composition of matter patent on motixafortide.

What was a key financial update for BioLineRx in November 2024?

In November 2024, BioLineRx and Ayrmid Ltd. entered into an exclusive license agreement to commercialize APHEXDA® (motixafortide) through.